

Effects of recombinant human thyroid stimulating hormone on ^{131}I therapy for the treatment of differentiated thyroid cancer

YILING GUO, YINGNAN ZHANG, ZUOWEI CHEN and ZHENFU XIN

Department of Nuclear Medicine, People's Hospital of Shenzhen, Shenzhen, Guangdong 518020, P.R. China

Received July 10, 2014; Accepted January 30, 2015

DOI: 10.3892/etm.2015.2330

Abstract. The aim of the present study was to compare the advantages and disadvantages of the combined application of recombinant human thyroid stimulating hormone (rhTSH) with thyroid hormone withdrawal (THW) and THW alone prior to ^{131}I therapy for the treatment of differentiated thyroid cancer. Four indicators were compared between the experimental group, who received a combined therapeutic method of rhTSH with THW, and the control group, who received THW therapy alone. With the exception of the elimination half-time of ^{131}I in the blood in the experimental group, which was significantly shorter compared with that in the control group, the other three indicators, including the urinary iodine concentration, the relative ^{131}I uptake ratio of the neck lesions and the one-time cure rate, were not significantly different between the two groups. In addition, the treatment efficacy of ^{131}I therapy exhibited no statistically significant difference between the experimental and control groups. However, in the experimental group, the residence time of ^{131}I in the blood was significantly shorter compared with that in the control group, indicating that the irradiation damage of radioactive iodine exposure to the non-target tissues was lower in the experimental group when compared with the control group. In addition, no evident hypothyroidism was observed in the patients. Thus, the combined application of rhTSH with THW prior to ^{131}I therapy was demonstrated to be superior to the THW therapy alone.

Introduction

Currently, radioiodine therapy is considered to be an effective but low-risk treatment method for cases of advanced differentiated thyroid cancer (DTC) (1-3). The treatment effect of ^{131}I depends on the ^{131}I uptake ability of the lesions, which has

two prerequisites. Firstly, the administration of an iodine diet is used to maintain the body in a low iodine environment, in order to avoid the dilution of non-radioactive iodine to radioactive iodine. Secondly, an improvement in the blood thyroid stimulating hormone (TSH) levels can be used to stimulate the ^{131}I uptake ability of the lesions. The TSH level can be elevated via two methods. One method is thyroid hormone withdrawal (THW) for approximately four weeks, which causes the patient to enter a hypothyroidism state, stimulating the production of endogenous TSH from the pituitary gland. An additional method is injections of recombinant human TSH (rhTSH), which improves the exogenous TSH level in the body (3). However, with regard to the injections of rhTSH, continual administration of thyroid hormone has been reported to dilute the concentration of radioactive iodine, thereby influencing the ability of the body to absorb the radioactive iodine (3). Thus, in the present study, a combined pretreatment program was designed, in which the withdrawal of thyroxine administration is conducted temporarily, but without causing overt hypothyroidism in the patients. This avoids the dilution effect of thyroxine on the radioactive iodine and maintains the patient's body in a relatively low iodine state. Subsequently, injections of rhTSH are administered, which is followed by ^{131}I therapy. The aim of the present study was to compare the advantages and disadvantages of the novel pretreatment program with THW therapy alone prior to ^{131}I therapy for the treatment of patients with DTC.

Materials and methods

Clinical data. In total, 15 patients who had been diagnosed with DTC in the Department of Thyroid and Breast Surgery at the People's Hospital of Shenzhen (Shenzhen, China) were enrolled in the study. All patients had undergone a near total resection of the thyroid and intended to undergo ^{131}I therapy in the People's Hospital of Shenzhen. ^{131}I was provided by Guangdong Xi'ai Nucleus Pharmaceutical Center (Guangzhou, China). The patients were divided into two groups. The experimental group (n=6) comprised three males and three females, with an age range of 48-72 years (mean age, 58.33 ± 9.69 years). The control group (n=9) comprised five males and four females, with ages ranging between 24 and 60 years (mean age, 41.22 ± 11.02 years). The study was conducted in accordance with the Declaration of Helsinki, and with approval from the Ethics Committee of the People's

Correspondence to: Professor Yingnan Zhang, Department of Nuclear Medicine, People's Hospital of Shenzhen, 1,017 Dongmei Road, Shenzhen, Guangdong 518020, P.R. China
E-mail: yingnanzhang@126.com

Key words: differentiated thyroid cancer, radioiodine therapy, ^{131}I , recombinant human thyroid stimulating hormone, urinary iodine

Table I. Comparison of the urinary iodine concentration prior to and following THW therapy in the two groups ($\mu\text{g/l}$).

Groups	Urinary iodine concentration prior to THW	Urinary iodine concentration following THW
Experimental	301.67 \pm 66.29	119.67 \pm 25.50 ^a
Control	299.78 \pm 63.55	107.33 \pm 18.49 ^b

Data are expressed as the mean \pm standard deviation. ^aP<0.01, vs. concentration prior to THW; ^bP>0.05, vs. experimental group following THW. THW, thyroid hormone withdrawal.

Table II. Comparisons of the indicators between the two groups following ¹³¹I therapy.

Groups	Elimination half-time of ¹³¹ I in the blood (h)	Ratio of the average pixel count of the ROI to the whole body	One-time cure rate (%)
Experimental	7.82 \pm 1.43	48.12 \pm 5.87	66.7
Control	9.76 \pm 1.74	46.96 \pm 10.11	55.6
Statistics	t=2.255, P=0.042	t=0.251, P=0.806	χ^2 =0.185, P=0.667

Data are expressed as the mean \pm standard deviation. ROI, region of interest.

Hospital of Shenzhen. Written informed consent was obtained from all the participants.

Treatment. Patients in the control group received an iodine diet, but withdrew from the administration of thyroxine for four weeks. The urinary iodine concentration was determined prior to ¹³¹I therapy. Patients in the experimental group received the same pretreatment, and the urinary iodine determination was performed in the same manner as for those in the control group. However, these patients also received an injection of 0.9 mg rhTSH (Thyrogen; Genzyme Corporation, Cambridge, MA, USA) at one and two days prior to the ¹³¹I therapy. The ¹³¹I dosage for clearing the residual thyroid was 2,590 MBq (70 mCi) for the two groups.

Calculation of the elimination half-time of ¹³¹I. At 2, 6, 9, 24 and 36 h after the patients were treated with ¹³¹I, a 0.5-ml blood sample was collected from each patient and placed in a FT603 well-type lead chamber (Beijing Nuclear Instrument Factory, Beijing, China) for radiocounting. The results were analyzed using SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL, USA) to calculate the elimination half-time of ¹³¹I in the blood.

Uptake ratio of ¹³¹I by the lesions. Patients in the two groups received a total body ¹³¹I scan using a single photon emission computed tomography system (Discovery VH; GE Healthcare, Milwaukee, WI, USA), on day seven following ¹³¹I therapy. On the scanogram, the neck lesion (region of interest, ROI) was sketched out and the ratio of the average pixel count in the ROI to the whole body was calculated.

Therapeutic effect. At the six-month follow-up examination, patients in the two groups underwent a neck ultrasound and serum thyroglobulin (Tg) analysis. For the patients with cervical lymph node enlargement and elevated serum Tg, a total

body ¹³¹I scan was performed. The clinical criteria indicating a recovery comprised a neck ultrasound examination revealing no thyroid or swelling lymph nodes, serum Tg concentrations of ≤ 2 ng/ml and a ¹³¹I scan showing no iodophilic hot lesions. In cases where these conditions were not achieved, the patients required additional ¹³¹I therapy. The one-time cure rate of the two groups was compared using the χ^2 test.

Statistical analysis. Measurement data are expressed as the mean \pm standard deviation, and SPSS 12.0 software was used for statistical analysis. Mean values of the urinary iodine concentration, the elimination half-time of ¹³¹I in the blood and the relative uptake ratio of the lesions in the two groups prior to and following THW were compared using the t-test. The one-time cure rate of the two groups was compared using the χ^2 test. P<0.05 was considered to indicate a statistically significant difference.

Results

Urinary iodine concentration. Prior to and at one week following THW therapy, the mean urinary iodine concentrations in the experimental group were 301.67 \pm 66.291 and 119.67 \pm 25.50 $\mu\text{g/l}$, respectively, which exhibited a statistically significant difference (t=10.25, P=0.008). However, the mean urinary iodine concentration in the experimental group at one week after THW (119.67 \pm 25.50 $\mu\text{g/l}$) exhibited no statistically significant difference when compared with the concentration in the control group at four weeks after THW therapy (107.33 \pm 18.49 $\mu\text{g/l}$; t=1.05, P=0.331; Table I).

Elimination half-time and uptake ratio of ¹³¹I. In the experimental group, the elimination half-time of ¹³¹I in the blood was 7.82 \pm 1.43 h, which was notably shorter when compared with the control group (9.76 \pm 1.74 h; t=2.255, P=0.042). The

ratio of the average pixel count of the ROI to the whole body was 48.12 ± 5.87 in the experimental group, showing no statistically significant difference with that in the control group (46.96 ± 10.11 ; $t=0.251$, $P=0.806$).

One-time cure rate. The one-time cure rate was 66.7% (4/6) in the experimental group and 55.6% (5/9) in the control group. As compared using the χ^2 test, no statistically significant difference was identified between the two groups ($\chi^2=0.185$, $P=0.667$; Table II).

Discussion

THW has traditionally been used to increase the serum TSH concentration, which can improve the sensitivity of DTC diagnosis, as well as optimize the capture and retention of radioactive iodine in the treatment of patients with DTC. However, THW can cause clinical hypothyroidism, resulting in the appearance of complications, such as cognitive impairment, mood disorders and other physical discomfort or health hazards, which consequently damage the patient's quality of life and ability to work (4-6). Since rhTSH was first approved by the Food and Drug Association as a diagnostic aid for DTC in December 1997, the hormone has been progressively and widely used in a number of European and American countries for the diagnosis, follow-up and treatment of DTC, with good results obtained (7-10).

The conventional method for elevating the TSH level is to stop the administration of levothyroxine (LT4) for approximately four weeks, in order to induce thyroid dysfunction. However, this method has a number of disadvantages. Firstly, patients have to endure the distress of hypothyroidism, which seriously affects their quality of life. Secondly, as a result of hypothyroidism, fluid retention and poor kidney function, the retention time of ^{131}I in the normal tissues is too long, which may substantially increase the radiative damage to the bone marrow, blood and other vital organs. Thirdly, for certain patients, THW is unable to effectively stimulate the pituitary gland to secrete TSH, thereby affecting the uptake of ^{131}I and the subsequent therapeutic effect. Finally, THW applied for a longer time period and continued TSH stimulation may have a risk of deteriorating the condition of the DTC. However, since rhTSH is yet to be introduced comprehensively in China, THW remains the primary method for DTC treatment in China.

Application of rhTSH may overcome the deficiencies of the THW method. However, if patients continue to receive thyroxine, the ability of the lesions to uptake ^{131}I may reduce due to the dilution of the non-radioactive iodine (7,11-13). In one LT4 molecule, the iodine atomic weight accounts for two-thirds of the entire LT4 molecular weight. Thus, it can be calculated that in the LT4 replacement therapy, a daily dose of 100-150 μg LT4 represents a daily supplement of 70-100 μg iodine. In this regard, oral administration of triiodothyronine and then an injection of rhTSH was proposed for patients prior to ^{131}I treatment, as this may reduce the dilution of non-radioactive iodine (7,12-15). In the present study, THW was applied for a short time, which was followed by the injection of rhTSH prior to ^{131}I therapy. The results revealed that the urinary iodine levels were similar between the experimental and control groups after THW, and the patients in the experi-

mental group did not appear to exhibit evident hypothyroidism. Furthermore, the results indicated that there was no statistically significant difference between the experimental and control groups with regard to the treatment effect of ^{131}I , which was consistent with a number of previous studies that reported no significant difference in the treatment effect of ^{131}I therapy between patients pretreated with rhTSH and THW (16-18).

In addition, the present study demonstrated that the retention time of ^{131}I in the blood in the experimental group was significantly shorter compared with that in the control group, indicating that the injection of rhTSH may reduce the irradiation damage of ^{131}I to the non-target tissues. Adjuvant treatment of rhTSH has been reported to be preferred for patients with a high risk of complications with regard to thyroid dysfunction or in those who are unable to produce a sufficient amount of endogenous TSH (19-23). However, whether this treatment method can be applied in the early stages of DTC in younger patients requires further study. The results of the current study also demonstrated that prior to treatment with ^{131}I , pretreatment with rhTSH combined with THW may cause less radioactive damage to the non-target organs of the patients with DTC compared with THW application alone. The combined treatment also avoided the occurrence of clinically significant hypothyroidism. However, due to the small number of patients included, the present study can only be used as a preliminary study investigating the role of rhTSH as an adjuvant treatment for patients with DTC. Therefore, the efficacy of the novel pretreatment method, using rhTSH combined with THW, in clinical practice should be further studied in the future.

References

1. Reiners C, Hanscheid H, Luster M, Lassmann M and Verburg FA: Radioiodine for remnant ablation and therapy of metastatic disease. *Nat Rev Endocrinol* 7: 589-595, 2011.
2. Biondi B, Pulcrano M, Pagano L and Lombardi G: Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer. *Biologics* 3: 9-13, 2009.
3. Klein HA: Radioiodine dilution due to levothyroxine when using recombinant human thyroid-stimulating hormone: case report and discussion. *Clin Nucl Med* 36: 899-903, 2011.
4. Klubo-Gwiedzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J and Wartofsky L: Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. *Thyroid* 22: 310-317, 2012.
5. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C and Pacini F: rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. *Endocr Relat Cancer* 12: 49-64, 2005.
6. Tuttle RM, Lopez N, Leboeuf R, *et al*: Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. *Thyroid* 20: 257-263, 2010.
7. Cooper DS, Doherty GM, Haugen BR, *et al*: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 16: 109-142, 2006.
8. Pacini F, Schlumberger M, Dralle H, *et al*: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* 154: 787-803, 2006.
9. Mazzaferri EL and Kloos RT: Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. *J Clin Endocrinol Metab* 86: 1447-1463, 2001.
10. Schroeder PR, Haugen BR, Pacini F, *et al*: A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. *J Clin Endocrinol Metab* 91: 878-884, 2006.

11. McLeod DS: Current concepts and future directions in differentiated thyroid cancer. *Clin Biochem Rev* 31: 9-19, 2010.
12. Elisei R, Schlumberger M, Driedger A, *et al*: Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. *J Clin Endocrinol Metab* 94: 4171-4179, 2009.
13. Phan HT, Jager PL, van der Wal JE, *et al*: The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. *Eur J Endocrinol* 158: 77-83, 2008.
14. de Meer SG, Vriens MR, Zelissen PM, Borel Rinkes IH and de Keizer B: The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer. *J Nucl Med* 52: 56-59, 2011.
15. Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. *JAMA* 295: 2164-2167, 2006.
16. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE and Devesa SS: Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. *Cancer Epidemiol Biomarkers Prev* 18: 784-791, 2009.
17. Tuttle RM, Leboeuf R and Martorella AJ: Papillary thyroid cancer: monitoring and therapy. *Endocrinol Metab Clin North Am* 36: 753-778, 2007.
18. Jonklaas J, Sarlis NJ, Litofsky D, *et al*: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. *Thyroid* 16: 1229-1242, 2006.
19. Gosnell JE and Clark OH: Surgical approaches to thyroid tumors. *Endocrinol Metab Clin North Am* 37: 437-455, 2008.
20. Van Nostrand D and Wartofsky L: Radioiodine in the treatment of thyroid cancer. *Endocrinol Metab Clin North Am* 36: 807-822, 2007.
21. Sawka AM, Brierley JD, Tsang RW, *et al*: An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. *Endocrinol Metab Clin North Am* 37: 457-480, 2008.
22. Brierley J, Tsang R, Panzarella T and Bana N: Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. *Clin Endocrinol (Oxf)* 63: 418-427, 2005.
23. Biondi B, Filetti S and Schlumberger M: Thyroid-hormone therapy and thyroid cancer: a reassessment. *Nat Clin Pract Endocrinol Metab* 1: 32-40, 2005.